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Abstract
Background: Rotational atherectomy (RA) has been proven to be efficient for the treatment of calcified 
and diffuse coronary artery lesions. However, the optimal burr-to-artery ratio (BtAR) remains unidenti-
fied as well as an influence of change in blood flow on long-term outcome. Aim of our study was to exam-
ine the association between long-term outcome, and both BtAR and change in coronary flow during RA.
Methods: We conducted a retrospective study including patients who underwent RA. Two independent 
observers calculated BtAR, pre- and postprocedural corrected Thrombolysis in Myocardial Infarction 
(TIMI) frame count (cTFC) for artery treated with RA. The long-term outcome was defined as all-cause 
mortality.
Results: Receiver operating characteristic curve analysis of BtAR determined threshold of 0.6106 for 
all-cause mortality detection with sensitivity 50.0%, specificity 90.8%, and area under the curve 0.730 
(p < 0.001). Kaplan-Meier survival analysis showed that the all-cause mortality rate in the group with 
the BtAR > 0.6106 is significantly higher compared to the patients with lower BtAR (hazard ratio [HR] 
3.76, 95% confidence interval [CI] 1.51–9.32; p < 0.001). Kaplan-Meier survival analysis revealed 
that the all-cause mortality rate in the group with impairment in coronary flow was significantly higher 
compared to group with cTFC difference ≤ 0 after RA (HR 3.28, 95% CI 1.56–9.31; p = 0.02).
Conclusions: Burr-to-artery ratio > 0.6106 is associated with worse prognosis of patients treated 
with RA. Patients showing post-RA impairment in blood flow in the target artery have worse prognosis. 
(Cardiol J)
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Over the past decades rotational atherectomy 
(RA) has been proven to be a safe and efficient 
method for treatment of calcified and diffuse 
coronary artery lesions [1–4]. Nevertheless, this 
strategy is still uncommonly used, with an applica-
tion rate as low as 0.8–3.1% of total percutaneous 
coronary interventions (PCI) in Europe [1]. In the 
Polish PCI registry, this value was even lower and 
amounted only 0.44% of PCI procedures [5, 6]. 
As demonstrated by previous studies, patients 
undergoing RA are significantly older than those 
treated with standard PCI [1]. Therefore, ageing 
of the population of cardiovascular patients should 
prompt resurgence of interest in RA that may even 
grow in the next years. Despite technological 
progress including the introduction of very high 
pressure and low-profile balloons, laser and orbital 
atherectomy, RA still occupies the first place among 
plaque modification techniques [4].
The technique of performing RA has evolved 
over the years. Although more aggressive debulking 
strategy with bigger burr sizes and burr-to-artery 
ratio (BtAR) > 0.7 was preferred in the past, the 
current guidelines recommend an opposite approach 
called “plaque modification strategy” based on using 
smaller burrs, with BtAR 0.5–0.6 [1, 2]. Previous 
studies showed that smaller burr sizing (BtAR < 0.7), 
compared with a more aggressive strategy, was re-
lated with similar procedural and angiographic suc-
cess rates, but was burdened with less angiographic 
complications and lower creatine kinase-myocardial 
band release during the procedure [7, 8]. There are 
only scarce literature data comparing both strategies 
in terms of long-term outcomes. 
The incidence of coronary artery flow impair-
ment in patients treated with RA is higher than after 
standard PCI [9–11]. There are several underlying 
mechanisms of this phenomenon, such as microcir-
culatory vasospasm, enhanced platelet activation 
and aggregation, and microvascular embolization 
of atherosclerotic debris [9, 12]. The occurrence of 
slow-flow in coronary arteries is usually associated 
with poor technique and inadequate burr size [1]. 
Administration of intracoronary nitrates, verapamil, 
sodium nitroprusside, or adenosine can improve the 
blood flow during the procedure [9, 12–14]. Previous 
studies showed that the occurrence of slow-flow is 
correlated with worse long-term prognosis [15]. 
However, significant slow-flow, defined as postpro-
cedural grade 0 or 1 according to Thrombolysis in 
Myocardial Infarction (TIMI) scale, is infrequent and 
occurs in 0.0–2.6% of cases [2]. The TIMI scale is 
an inaccurate and operator-dependent method, nev-
ertheless, it is still commonly used for assessment 
of postprocedural coronary blood flow and even de-
spite clear slowing of the blood flow is often judged 
as TIMI 3 [16]. In our study, we focused on BtAR 
as a key difference between debulking and plaque 
modification strategies and on difference in post-RA 
coronary flow in the target vessel. The aim of our 
study was to examine whether BtAR and coronary 
flow after the procedure are associated with long- 
-term outcomes in patients undergoing RA. 
Methods
Study design and patients 
This is a retrospective, double-center study 
including patients who underwent RA at the De-
partment of Cardiology and Internal Medicine of 
the University Hospital No. 1 in Bydgoszcz and 
at the Department of Cardiology and Structural 
Heart Diseases of the Medical University of Silesia 
in Katowice between January 2005 and February 
2017. During that time period a total of 232 RA pro-
cedures were performed. Procedural success was 
defined as success in facilitating stent delivery with 
residual stenosis < 50% and without severe proce-
dural complication (e.g., inability to insert guiding 
catheter/rotablator burr through the stenotic lesion 
or occurrence of severe dissection/perforation). 
The procedures assessed as unsuccessful were 
not included in the further analysis. 52 cases were 
excluded and 180 patients were eventually enrolled 
with stenosis treated with RA for the analysis. The 
exclusion criteria were more than one RA procedure 
in a single patient (n = 6), unsuccessful passage 
of the burr through the stenotic lesion (n = 7) or 
inability to calculate BtAR due to technical issues 
(n = 39). The analysis of coronary blood flow chang-
es was performed, with data limited to the center in 
Bydgoszcz. 21 patients were excluded, (12 patients) 
due to inability to calculate the corrected TIMI 
frame count (cTFC) before and after the procedure, 
or administration of glycoprotein IIb/IIIa inhibitors 
during RA (9 patients). The need for performing RA 
in each case was evaluated by the operator based 
on two main indications: presence of uncrossable 
lesions and inability to sufficiently dilate the lesion 
with a balloon. In cases when more than one burr 
size was used the largest size was included in the 
analysis. All study participants received pharmaco-
therapy according to the recommendations of the 
European Society of Cardiology valid at the time of 
the procedure. Clinical and procedural data were col-
lected from patient medical records. Follow-up data 
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were collected from the Polish National Health Fund 
database. The study was conducted in accordance 
with the Declaration of Helsinki and Good Clinical 
Practice guidelines and was approved by the Ethics 
Committee of Nicolaus Copernicus University in 
Torun, Collegium Medicum in Bydgoszcz (approval 
number KB 56/2020). The primary clinical endpoint 
was defined as all-cause mortality. 
Angiograms
Two independent observers in both centers 
trained in angiogram assessment and blinded to 
other clinical data, calculated BtAR. The definition 
and calculation method of BtAR was similar as 
reported in previous studies [17]. The measure-
ments from both observers were then averaged 
to give the final result. The cTFC was defined as 
the number of frames required for contrast dye to 
reach the first standard distal coronary landmark 
and was evaluated using the technique described 
by Gibson et al. [16]. The difference between the 
postprocedural and preprocedural cTFC was evalu-
ated to reflect the changes in coronary artery blood 
flow. Both preprocedural and postprocedural cTFC 
were examined directly before and after RA, re-
spectively. All angiograms were registered at 12.5 
frames/s. All disputable issues and disagreements 
were resolved by a third independent observer. 
The primary angiographic endpoint was defined 
as post-RA cTFC. The angiograms were analyzed 
using OsiriX Lite software (Pixmeo SARL) and 
CAAS QCA software (Pie Medical Imaging BV). 
Statistical analysis 
The statistical analysis was performed using 
the Statistica 13.0 package (StatSoft, Tulsa, USA) 
and MedCalc 15.8 (MedCalc Software, Ostend, 
Belgium). Continuous variables were presented as 
medians with interquartile ranges or means with 
standard deviation (SD). Categorical variables were 
expressed as the number of patients presenting the 
given feature and the percentage of patients in the 
analyzed group. The optimum cut-off points for the 
association between BtAR and all-cause mortality 
was determined using receiver operator charac-
teristics curve analysis. The Shapiro-Wilk test 
demonstrated that the continuous variables inves-
tigated were not normally distributed. Therefore, 
comparisons of continuous variables between the 
two groups were analyzed with the Mann-Whitney 
unpaired rank sum test. Categorical variables were 
compared using the c2 test and with the Yates’ 
correction if required. The survival analyses were 
performed with the Kaplan-Meier method and the 
log-rank test. Aforementioned calculations were 
made for a 6-year time period (from the procedure 
to patient’s death) because after that time period 
the number of patients remaining in the analysis 
group was very limited and could potentially in-
crease the risk of calculation bias. Differences were 
considered significant at p < 0.05.
Results
Baseline characteristics
The mean age (SD) in the study group was 
71.8 (9.0) years with a prevalence of men (65.0%). 
The mean BtAR (SD) was 0.4951 (0.1158). A total 
of 28 (15.6%) patients died with a mean (SD) of 
745.2 (848.1) days from the procedure to death. 
Detailed characteristics of the study population is 
presented in Table 1. 
Burr-to-artery ratio 
The optimal BtAR cut-off point for predic-
tion of all-cause mortality was 0.6106 (sensitivity 
Table 1. Baseline clinical characteristics of the study population including division according to burr-to-
-artery-ratio (BtAR) threshold. 
All patients enrolled  
in the study (n = 180)
BtAR ≤ 0.6106  
(n = 152)
BtAR > 0.6106  
(n = 28)
P
Male sex 117 (65.0%) 97 (63.8%) 20 (71.4%) 0.58
Age 71.8 (9.0) 72.0 (9.0) 70.6 (9.1) 0.45
Hypertension 136 (75.6%) 119 (78.3%) 17 (60.7%) 0.08
Diabetes 96 (53.3%) 85 (55.9%) 11 (39.3%) 0.16
Prior MI 91 (50.6%) 78 (51.3%) 13 (46.4%) 0.79
Body mass index 28.2 (4.6) 28.3 (4.4) 27.8 (4.1) 0.62
Ejection fraction 50 (39.75–55.0) 50 (39.5–55.0) 43 (39.0–51.0) 0.37
Mean values (standard deviation), median (interquartile range), or number (%); MI — myocardial infarction
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50.0%, specificity 90.8%, area under curve 0.730; 
p < 0.001). Based on this BtAR threshold, the 
patients were divided into two groups, with the 
majority of them (84.4%) falling into the BtAR 
≤ 0.6106 group. Both groups did not differ in terms of 
baseline clinical characteristics (Table 1). Duration 
of the procedure and location of stenosis were simi-
lar in both groups (Table 2). For patients with BtAR 
≤ 0.6106 smaller burrs (median burr size 1.5 [1.25–
–1.5] vs. 1.5 [1.25–1.75], p = 0.006), larger stents 
(minimum stent diameter [mm]: 2.75 [2.5–3.0] 
vs. 2.5 [2.25–3.0], p = 0.03; maximum stent di-
ameter [mm]: 3.0 [2.75–3.5] vs. 2.5 [2.5–3.5], 
p = 0.02; median stent diameter [mm]: 3.0 [2.67–
–3.25] vs. 2.5 [2.5–3.0], p = 0.01) and smaller 
catheters were used (catheter size [Fr]: 6 [66.5%], 
7 [29.6%], 8 [3.9%] vs. 6 [67.8%], 7 [14.3%], 
8 [17.9%], p = 0.009).
The Kaplan-Meier survival analysis (Fig. 1) 
showed a significantly higher all-cause mortality 
rate in the group with BtAR > 0.6106 compared 
with the patients with a lower BtAR (hazard ratio 
[HR] 3.76, 95% confidence interval [CI] 1.51–9.32; 
p < 0.001).
Changes in coronary artery blood flow
A total of 62 patients for whom the cTFC was 
evaluated were divided into two groups based on the 
difference between the postprocedural and preproc-
edural values of cTFC. Patients showing impairment 
Table 2. Angiographic characteristics of the study population including division according to burr-to-
-artery-ratio (BtAR) threshold.
All patients  
enrolled in the 
study (n = 180)
BtAR £ 0.6106  
(n = 152)
BtAR > 0.6106  
(n = 28)
P
Duration of the procedure [min] 80.0 (60.0–110.0) 80.0 (60.0–110.0) 66.0 (58.5–98.5) 0.31
Contrast volume [mL] 200.0 (150.0–250.0) 200.0 (150.0–250.0) 210.0 (155.0–260.0) 0.32
Location of treated stenosis: 70 (38.9%) 62 (40.8%) 8 (28.6%) 0.86
LAD
RCA 57 (31.7%) 50 (32.9%) 7 (25.0%) 0.54
Cx 39 (21.6%) 29 (19.1%) 10 (35.7%) 0.09
OM 14 (7.8%) 11 (7.2%) 3 (10.7%) 0.80
Burr size [mm] 1.5 (1.25–1.5) 1.5 (1.25–1.5) 1.5 (1.25–1.75) 0.006
Minimum stent diameter [mm] 2.75 (2.5–3.0) 2.75 (2.5–3.0) 2.5 (2.25–3.0) 0.03
Maximum stent diameter [mm] 3.0 (2.5–3.5) 3.0 (2.75–3.5) 2.5 (2.5–3.5) 0.02
Average stent diameter [mm]* 3.0 (2.5–3.25) 3.0 (2.67–3.25) 2.5 (2.5–3.0) 0.01
Usage of glycoprotein IIb/IIIa inhibitors 16 (8.9%) 12 (7.9%) 4 (14.3%) 0.47
Total stent length [mm] 38.0 (22.0–52.0) 38.0 (23.0–52.0) 42.0 (18.0–59.0) 0.74
Catheter size [Fr]: 0.009
6 66.7% 66.5% 67.8%
7 27.2% 29.6% 14.3%
8 6.1% 3.9% 17.9%
Values are median (interquartile range) or number (%); *In case of implantation more than one stent in target vessel an average diameter for 
all implanted stents was calculated; LAD — left anterior descending artery; RCA — right coronary artery; Cx — circumflex coronary artery; 
OM — obtuse marginal artery
Figure 1. Survival after rotational atherectomy (RA) by 
burr-to-artery ratio (BtAR) after division into two groups.
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in blood flow in the target artery (cTFC difference 
> 0) had a lower body mass index (mean [SD], 26.7 
[3.9] vs. 29.8 [4.7], p = 0.04) with no other baseline 
or procedural differences in comparison to patients 
presenting cTFC difference ≤ 0 (Table 3).
The Kaplan-Meier survival analysis (Fig. 2) re-
vealed a significantly higher all-cause mortality rate 
in the group with impaired post-RA coronary artery 
blood flow (cTFC difference > 0) compared with 
patients with preserved coronary flow with cTFC 
difference ≤ 0 (HR 3.28, 95% CI 1.56–9.31; p = 0.02).
Discussion
The main finding of this study is that BtAR 
higher than 0.6106 and impaired postprocedural 
coronary flow (cTFC difference > 0) are associated 
with almost 4-times and over 3-times higher risk 
of mortality in those groups, respectively.
The increase in mortality found in cases with 
higher BtAR can be explained by a higher com-
plication rate associated with a more aggressive 
debulking strategy [7]. Other potential causes of 
this phenomenon include higher debris produc-
tion, increased platelet activation and aggregation, 
microvascular embolization resulting in heart sys-
tolic dysfunction [18]. The optimal BtAR remains 
unidentified, however the current guidelines rec-
ommend the burr size of < 0.7 [1] or < 0.6 [2] of 
the vessel diameter. Recently published studies 
reflecting implementation of recommendations 
into clinical practice reported the BtAR < 0.6 
Table 3. Baseline clinical and angiographic characteristics of the study population regarding corrected 
Thrombolysis in Myocardial Infarction frame count (cTFC) difference.
All patients enrolled 
in the study (n = 62)
cTFC difference £ 0 
(n = 38)
cTFC difference > 0 
(n = 24)
P 
Male sex 38(61.3%) 21 (55.3%) 17 (70.8%) 0.22
Age 71.1 (9.0) 72.7 (8.9) 68.5 (8.8) 0.07
Arterial hypertension 42 (67.7%) 25 (65.8%) 17 (70.8%) 0.84
Diabetes type 2 33 (53.2%) 17 (44.7%) 16 (66.7%) 0.12
Prior MI 30 (48.4%) 16 (42.1%) 14 (58.3%) 0.26
Body mass index 28.3 (4.5) 29.3 (4.7) 26.7 (3.9) 0.04
Ejection fraction 42.5 (38.0–49.) 40 (35.5–49.25) 47 (41.25–49.0) 0.17
Duration of the procedure [min] 65.0 (50.0–90.0) 65.0 (55.0–90.0) 60.0 (50.0–90.5) 0.56
Contrast volume [mL] 182.0 (140.0–270.0) 182.0 (145.0–261.0) 180.0 (137.5–278.0) 0.79
Location of treated stenosis:
LAD 9 (14.5%) 7 (18.4%) 2 (8.3%) 0.47
RCA 23 (37.1%) 14 (36.8%) 9 (37.5%) 0.96
Cx 20 (32.6%) 13 (34.2%) 7 (29.2%) 0.68
OM1 7 (11.3%) 4 (10.5%) 3 (12.5%) 0.86
OM2 3 (4.8%) 0 (0%) 3 (12.5%) 0.28
Burr size [mm] 1.25 (1.25–1.5) 1.25 (1.25–1.5) 1.5 (1.25–1.5) 0.12
Minimum stent diameter [mm] 2.5 (2.5–3.0) 2.5 (2.375–3.0) 2.625 (2.5–3.0) 0.57
Maximum stent diameter [mm] 3.0 (2.5–3.5) 3.0 (2.5–3.5) 3.0 (2.5–3.5) 0.21
Average stent diameter [mm]* 2.8 (2.5–3.0) 2.775 (2.5–3.0) 3.0 (2.5–3.25) 0.27
Total stent length [mm] 38.5 (20.0–51.5) 40.5 (23.0–53.0) 38.0 (19.5–50.0) 0.79
Catheter size [Fr]:
6 71.0% 71.0% 70.8% 0.42
7 22.6% 23.7% 20.8%
8 6.4% 5.3% 8.3%







Mean values (standard deviation), median (interquartile range) or number (%); *In case of implantation more than one stent in target vessel 
an average diameter for all implanted stents was calculated; MI — myocardial infarction; LAD — left anterior descending artery; RCA — right 
coronary artery; Cx — circumflex coronary artery; OM1 — first obtuse marginal artery; OM2 — second obtuse marginal artery
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[3, 19, 20] or even < 0.5 [21, 22] for the overall 
study population. The mean BtAR (SD) calcu-
lated for all patients in the present study was 0.50 
(0.12). The beneficial effect of RA performed with 
lower BtAR has been demonstrated in previously 
published studies [7, 17, 20]. One of the earli-
est studies regarding RA, by Kaplan et al. [17], 
revealed that the need for vessel revasculariza-
tion is decreased in patients with BtAR 0.6–0.85. 
Randomized CARAT trial [7] revealed that RA 
performed with smaller burrs (BtAR ≤ 0.7) pro-
vided similar procedural success, but with a lower 
angiographic complication rate, in comparison to 
a more aggressive strategy. Cuenza et al. [20] 
reported significantly higher BtAR in patients 
who developed major adverse events. In the cur-
rent study, patients with higher BtAR had worse 
long-term prognosis, thus supporting the need for 
less aggressive treatment. Despite benefits of a 
smaller burr sizing, evidence regarding the lower 
limit of optimal BtAR range is very scarce. Brown 
et al. [23] demonstrated that RA performed even 
with BtAR < 0.5 can provide low complication and 
high success rates. Therefore, in order to find the 
optimal burr size, it is recommended to start RA 
with the smallest possible burr size and increase 
it until a favorable result is achieved [1, 2].
In order to overcome the subjectivity and im-
precision of the TIMI scale, the cTFC difference 
was used as a more precise and objective tool for 
assessment of coronary blood flow [16]. It was 
found that impairment of coronary blood flow was 
correlated with higher mortality. 
Several studies [24–30] investigated the in-
fluence of preprocedural or postprocedural blood 
flow in the target artery on short and long-term 
outcome, but the majority focused on patients with 
myocardial infarction for whom RA is rather the last 
interventional option [19]. According to available 
research, this is the first study to evaluate the as-
sociation between a change in coronary blood flow 
during RA and long-term outcomes.
The results of the GUSTO IIb [31] and 
RAPPORT [32] trials showed that patients with 
suboptimal coronary blood flow (TIMI ≤ 2) after 
primary PCI had worse prognosis (with mortality 
rates of TIMI 3 vs. TIMI ≤ 2 of 1.5% and 10.2%, 
respectively, p < 0.001) during 30 days of obser-
vation. De Luca et al. [25] noted that in high-risk 
patients treated with primary PCI due to acute 
myocardial infarction the preprocedural TIMI flow 
grade 3 was an independent predictor of 1-year 
survival. Mehta et al. [26] reported a strong as-
sociation between final TIMI grade ≤ 2 and both 
in-hospital and 1-year adverse events, although 
they noticed that TIMI ≤ 2 which occurred less 
commonly after primary PCI. A study by Ndrepepa 
et al. [27] revealed an association between post-
procedural TIMI flow grade and 1-year mortality in 
patients with acute coronary syndrome treated with 
PCI, however no correlation was found between 
preprocedural TIMI score and mortality. 
Gibson et al. [28] demonstrated lower 90-min-
ute cTFC after thrombolysis administration to be 
a predictor of improved in-hospital and 1-month 
clinical outcomes [28] and 2-year survival [29]. Im-
portantly, the authors noticed that among patients 
with normal coronary blood flow (TIMI grade 3, 
cTFC ≤ 40), there may be lower- and higher-risk 
subgroups [28]. Although thrombolytic therapy is 
currently not recommended for patients with myo-
cardial infarction as a primary strategy, this finding 
should be taken into consideration regarding the 
results of the present study, since normal flow after 
RA was observed in the vast majority of patients 
(98.4% and 93.5% according to the TIMI scale or 
cTFC, respectively). French et al. [30] showed that 
the cTFC (3 weeks after myocardial infarction) is 
an independent predictor of 5-year survival, how-
ever no relationship was found regarding 10-year 
survival. The authors reported also that the cTFC 
method, although yielding additional prognostic 
information, was not superior to TIMI flow grade.
Figure 2. Survival after rotational atherectomy (RA) by 
changes in coronary blood flow; cTFC — corrected 
Thrombolysis in Myocardial Infarction frame count.
Patients with cTFC difference £ 0
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Limitations of the study
Several limitations of the present study should 
be noted. The main limitation of the present study 
is its retrospective design. On the other hand, the 
use of objective quantitative data as the BtAR and 
the mortality hard endpoint can mitigate potential 
confounding arising from a retrospective design. 
The next limitation is a relatively low number of 
patients included in the final analysis. Neverthe-
less, it should be underlined that RA is remains 
a rarely performed procedure, especially in Poland. 
Therefore this study showed results of one of the 
largest Polish cohorts of patients who underwent 
this procedure. Another limitation, potentially in-
fluencing the results, is the extended duration of 
study period, possibly resulting in heterogeneity of 
the study population with regard to the evolution 
of available procedural techniques and pharmaco-
therapy over the last decade. Furthermore, only 
all-cause mortality data were able to be retrieved, 
which rendered a complementary analysis of car-
diovascular deaths impossible. Finally, the cTFC 
parameter difference introduced in the current 
study, although prognostically useful, is time-
consuming to calculate and therefore its use in 
everyday practice may be limited.
Conclusions
This is the first study to evaluate the associa-
tion between long-term outcome of patients treated 
with RA and BtAR as well as changes in coronary 
blood flow. The BtAR higher than 0.6106 and im-
pairment of blood flow assessed with the cTFC 
difference were associated with worse survival. 
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